Loading...
Market
What will be the response of major pharmaceutical companies to the Florida grand jury report by mid-2025?
2
Resolution / Starting Odds
Acknowledgement • 25%
Denial • 25%
No comment • 25%
Legal action • 25%
Official statements or press releases from major pharmaceutical companies
Story
Florida Grand Jury, at DeSantis's Request, Finds No Criminal Activity in COVID-19 Vaccine Probe, Recommends Policy Changes
Jan 7, 2025, 10:30 PM
A statewide grand jury in Florida, convened at the request of Governor Ron DeSantis, has concluded its investigation into the development and safety of COVID-19 vaccines, finding no evidence of criminal activity. The grand jury's final report, released on Tuesday, highlighted 'profound and serious issues' related to the transparency and process of vaccine development and safety surveillance in the United States. Despite not finding any illegal actions, the jury recommended policy changes, including increased transparency around clinical trials and a ban on advertisements for pharmaceutical drugs. The investigation was initiated in 2022 amidst DeSantis's campaign for the Republican presidential nomination, where he positioned himself against pandemic lockdowns and mask mandates. The report also noted that 'Big Pharma' engaged in a 'pattern of deceptive and obfuscatory behavior,' allegedly hiding adverse effects of the vaccines to rake in billions in profit.
View original story
Similar markets
Other • 25%
Acknowledge issues and propose changes • 25%
Deny allegations and defend actions • 25%
No official response • 25%
Other response • 25%
Support the proposal • 25%
Oppose the proposal • 25%
Remain neutral • 25%
Investigation not concluded • 25%
Positive impact • 25%
No significant impact • 25%
Significant negative impact • 25%
Some issue statements • 25%
All issue statements • 25%
Issue joint statement • 25%
None issue statements • 25%
New regulations on vaccine transparency • 25%
Investigations into pharmaceutical companies • 25%
No legislative action • 25%
Other • 25%
No significant change • 25%
Increased trust in vaccines • 25%
Decreased trust in vaccines • 25%
Other • 25%
File for bankruptcy again • 25%
No significant actions • 25%
Rebrand or restructure • 25%
Reach new settlements with other firms • 25%
Other • 25%
Product reformulation • 25%
Compliance • 25%
Legal challenge • 25%
No • 50%
Yes • 50%
Increased security measures • 25%
No significant reaction • 25%
Public condemnation only • 25%
Policy changes or reforms • 25%
Johnson & Johnson • 25%
Moderna • 25%
Other • 25%
Pfizer • 25%
